Gellekink et al 1 addressed the important issue of genetic variation in the human DHFR gene and have identified two novel polymorphisms in the region 5 0 of exon 1. They have referred to sequence ref NM_000791 to determine the transcription initiation site and from this the inferred promoter region. This information was used to choose polymorphisms for a further study of association with folate and homocysteine levels. NM_000791 is a sequence carrying six copies of the 9 bp upstream repeat 1 with its 3 0 end at -492 with respect to the initiation codon in a region usually described as the minor promoter.
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However, up to 99% of DHFR expression derives from the major promoter and initiates at À71.
2 The novel polymorphism referred to by Gellekink et al 1 as delG À82
and the polymorphism referred to as G4A À95 (rs10168) that occur close to the transcription initiation point of the major promoter are thus of considerable interest. In particular, delG À82 alters a region protected against DNase I digestion 3 and close to a site, which affects gene expression in mutagenesis experiments. 4 The allele frequencies of delG À82 and G4A À95 are markedly different from any of the alleles typed in the association part of the study, 1 suggesting that the effects of delG À82 and G4A
À95 would not have been detected as a result of linkage. It will now be of great interest to determine the effects of delG À82 and G4A À95 on the metabolism of folic acid and dihydrofolate, and in response to antifolate drugs.
